From the TWiV Vault Netcast

In his weekly clinical update, Dr. Griffin discusses surveillance to track progress toward poliomyelitis eradication, genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3, evaluation of Oseltamivir used to prevent hospitalization in outpatients with Influenza, viral emissions into the air and environment after SARS-CoV-2 human challenge, has COVID-19 threatened routine childhood vaccination, successful treatment of persistent symptomatic COVID-19 infection with extended duration Nirmatrelvir/Ritonavir, anemia as a risk factor for disease progression in patients admitted for COVID-19, impact of fatigue as the primary determinant of functional limitations among patients with post-COVID-19 syndrome, post-COVID condition in patients with inflammatory rheumatic diseases, outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months, metformin reduces SARS-CoV-2 in a Phase 3 randomized placebo controlled clinical trial, persistent serum protein signatures define an inflammatory subcategory of long COVID, and the relevance of pacing strategies in managing symptoms of post-COVID-19 syndrome.

In his weekly clinical update, Dr. Griffin discusses estimates of SARS-CoV-2 seroprevalence and incidence of primary SARS-CoV-2 infections among blood donors, by COVID-19 vaccination status, smart thermometer–based participatory surveillance to discern the role of children in household viral transmission during the COVID-19 pandemic, COVID-19 vaccine mandates, changing severity and epidemiology of adults hospitalized with COVID-19 in the United States after introduction of COVID-19 vaccines, effectiveness of COVID-19 treatment with Nirmatrelvir–Ritonavir or Molnupiravir among U.S. veterans, national trends in anticoagulation therapy for COVID-19 hospitalized adults in the United States, development of a definition of postacute sequelae of SARS-CoV-2 infection, neuroinflammation after COVID-19 with persistent depressive and cognitive symptoms, long COVID clinical phenotypes up to six months after infection identified by latent class analysis of self-reported symptoms, and coronary microvascular health in symptomatic patients with prior COVID-19 infection.

In his weekly clinical update, Dr. Griffin discusses the potential for recurrent Mpox outbreaks among gay, bisexual, and other men who have sex with men, association between SARS-CoV-2 variants and frequency of acute symptoms, prospective study of key correlates for household transmission of SARS-CoV-2, Pfizer’s PAXLOVID™ receiving FDA approval for adult patients at high risk of progression to severe COVID-19, efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients hospitalized with COVID-19, development of a definition of postacute sequelae of SARS-CoV-2 infection, COVID-19 and risk for mental disorders among adults in Denmark, risk of new post-COVID mental disorders higher only in older patients.

In his weekly clinical update, Dr. Griffin discusses the CDC HIV surveillance report, FDA voted in favor of approving the Abrysvo vaccine, canine olfactory detection of SARS-CoV-2-infected humans, safety of the BNT162b2 COVID-19 vaccine in children aged 5 to 17 years, and statement on the antigen composition of COVID-19 vaccines.

In his weekly clinical update, Dr. Griffin discusses variant specific clinical performance of a SARS-CoV-2 rapid antigen test with focus on omicron VOC, ventilation in buildings, COVID-19 mortality among selective serotonin reuptake inhibitor users, risk of post-acute sequelae of SARS-CoV-2 infection associated with pre-coronavirus disease obstructive sleep apnea diagnoses, trajectories of the evolution of post COVID-19 condition, and efficacy of cognitive behavioral therapy targeting severe fatigue following COVID-19.